Table of Contents Table of Contents
Previous Page  521 / 812 Next Page
Information
Show Menu
Previous Page 521 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S517

Methods

The sample is based on the large Northern Finland Birth

Cohort 1966. Temperament traits were measured at age 31 years

using the Temperament and Character Inventory. At the age of

46 years depressive symptoms were measured using the Beck

Depression Inventory – II (BDI). The sample included those with

self-reported life-time depression history at age 46 years but not

yet at age 31 years (

n

= 298). Temperament at age 31 years was used

to predict remission (BDI

13) at age 46 years using logistic regres-

sion analysis, with gender and educational level as confounders.

Cohen’s d was used as effect size measure.

Results

Two hundred and one (67.4%) of individuals with self-

reported depression were on remission at the follow-up. Low

harm avoidance (total scale, and subscales anticipatory worry, shy-

ness, and fatigability), low impulsiveness and high exploratory

excitability (subscales of novelty seeking), and low sentimentality

(subscale of reward dependence) predicted significantly remission

with effect sizes between 0.28 and 0.45, highest effect being inharm

avoidance.

Conclusions

Different temperament traits were able to predict

remission status in depression. Effect sizes were between small and

moderate. Temperament may associatewith treatment response in

depression.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1509

EV525

The importance of art therapy in the

integrative treatment of recurrent

depressive disorder – case study

J. Pavlovic Stojkovic

1

, M. Milosavljevic

1 ,

, M. Vukovic

1

, L. Vidic

1

,

D. Lecic Tosevski

1 , 2 , 3

1

Institute of Mental Health, Clinical Department for Crisis Situations

and Affective Disorders, Belgrade, Serbia

2

Serbian Academy of Sciences and Arts, Medicine, Belgrade, Serbia

3

University of Belgrade, Medical Faculty, Belgrade, Serbia

Corresponding author.

An integrative treatment of patients with affective disorders dur-

ing hospitalisation also includes art therapy. Art therapy, as a form

of expressive therapy, uses the creative process to encourage com-

munication, expression of feelings and offers the space for mutual

mirroring. This paper presents a patient who has been treated

for approximately five years under the diagnosis of a recurrent

depressive disorder (F33) and mixed personality disorder (F61).

The patient has been experiencing unrecognised and untreated

problems of the depression spectrum since 1993, when he took

part in the Yugoslav war. The main issue was the somatic symp-

toms (headaches, nausea etc). Another major problem during his

psychiatric treatment and an additional cause of unsatisfactory

therapeutic effect was his inability to verbalise his feelings. In the

course of art therapy, when the patient was given a topic “How I see

myself in five years”, he drew a man who appeared to be sleeping

and explained that he could not see himself in five years’ time, since

he would not be alive at the time and that he could not see a way

out of the current situation. With the help of a supportive group, for

the first time since the beginning of his treatment, he spoke about

his thoughts and feelings of hopelessness, sorrow, alienation and

loneliness. This enabled new insight into the patient’s depression.

This clinical example shows how art therapy and reaction of the

group, which was supportive and highly associative, can turn the

non-verbal into verbal and non-communication into communica-

tion.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1510

EV526

Toward evidence-based medical

statistics: Re-evaluate the efficacy of

antidepressants by using Bayes factors

R. Monden

1 ,

, D.V. Stijn

1

, W. Klaas

1

, R. Annelieke

1

, M. Richard

2

,

W. Eric-Jan

3

1

University Medical Center Groningen, Psychiatry, Groningen,

Netherlands

2

Cardiff University, School of Psychology, Cardiff, United Kingdom

3

University of Amsterdam, Psychology, Amsterdam, Netherlands

Corresponding author.

Introduction

Studies have been reported the similar efficacy of

antidepressants (effect size around 0.3), and it is difficult for clin-

icians to select an antidepressant. This may partly due to the use

of a p<.05 null-hypothesis significance testing (NHST) framework

to evaluate “substantial evidence”. This framework only allows

dichotomous conclusions and does not quantify the strength of

evidence supporting efficacy. In addition, meta-analyses based on

publications may offer positively biased results due to selective

publications.

Objectives

Demonstrate that the Bayesian framework can pro-

vide valuable information on the strength of the evidence for drug

efficacy.

Aims

Re-evaluate the efficacy of FDA-approved antidepressants

applied to anxiety disorders and depression by means of Bayes

factors.

Methods

To avoid selective publication, data of double-blind

placebo-controlled trials for FDA-approved antidepressants for the

treatment of anxiety disorders and depressionwere extracted from

the FDA. Bayes factors (BFs) were calculated and comparedwith the

results obtained under NHST framework.

Results

A large variance of evidence for the efficacy of antide-

pressants was found for both depression and anxiety disorders.

Among trials providing “substantial evidence” according to the

FDA for anxiety disorders, only 27 out of 59 dose groups obtained

strong support for efficacy according to the typically used cut-off

of BF

20. For depression, all FDA-approved antidepressants had

BF

20, except for bupriopion. Moreover, it was shown that the

tested antidepressants can be differentiated based on the strength

of evidence and effect size.

Conclusions

The BFs quantified the comparative evidence base

for the efficacy of antidepressants.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1511

EV527

Anxiety, depression, perceived social

support and quality of life in

Malaysian breast cancer patients: A

1-year prospective study

C.G. Ng

1 ,

, S. Mohamed

2

, M.H. See

3

, F. Harun

4

, A.H. Sulaiman

1

,

N.Z. Zainal

1

, N.A. Taib

3

1

University of Malaya, Department of Psychological Medicine, Kuala

Lumpur, Malaysia

2

Faculty of Medicine-Universiti Teknologi MARA, Department of

Psychiatry, Kuala Lumpur, Malaysia

3

University Malaya Medical Centre, Department of Surgery, Kuala

Lumpur, Malaysia

4

University of Malaya, Department of surgery, Kuala Lumpur,

Malaysia

Corresponding author.

Background

Depression and anxiety were common psychiatric

morbidity among breast cancer patient. This study aims to study the

level of depression, anxiety, QoL and PSS among Malaysian breast